Targeting E2F8 sensitizes gemcitabine-resistant gallbladder cancer to PARP inhibitors by disrupting RRM2-driven DNA repair.

ABSTRACT:

SUBMITTER: Ni X 

PROVIDER: S-EPMC12822184 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature